Astec Lifescienc Q1 FY27 Results (NSE: ASTEC)
Signal: Loss narrowed
The read
Q1FY27 consolidated revenue fell 8.3% YoY to ₹83.56 Cr, but operating loss narrowed sharply (OPM -0.80% vs -12.07% a year ago) — 6th consecutive quarter of margin expansion — as fixed-cost absorption improved and finance costs dropped 30%. Net loss improved 43.4% YoY to -₹18.71 Cr. However, raw material cost spiked to 91.3% of revenue (vs 65.2% a year ago), indicating severe input-cost headwind; the margin improvement is entirely from lower fixed costs, not pricing power. The company remains deeply loss-making, albeit at a moderating pace.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹83.56 Cr | -8.3% | -47.3% |
| EBIT | ₹-18.74 Cr | 43.2% | |
| Net profit | ₹-18.71 Cr | 43.4% | |
| EPS | ₹-8.4 | 50.1% | |
| EBIT margin | -0.80% |
P&L walk
Revenue declined 8.3% YoY (₹83.56 Cr vs ₹91.08 Cr) on a 2608bps jump in raw material cost to 91.3% of sales, yet operating loss narrowed sharply due to improved absorption of fixed costs; EBITDA margin (OPM) improved 1126bps YoY to -0.80% — 6th consecutive quarter of margin expansion.
Segments
Single reportable segment: Agrochemicals; no segment table provided.
Key positives
- 6th consecutive quarter of OPM expansion — from -66.67% in Q1FY25 to -0.80% in Q1FY27, a 6587bps cumulative improvement over six quarters.
- Net loss narrowed 43.4% YoY to -₹18.71 Cr, driven by improved operating margin and 30% lower finance costs.
- Debt-equity ratio improved to 0.98 from 2.95 a year ago, reflecting deleveraging.
Key concerns
- Revenue declined 8.3% YoY — top-line contraction limits profitability recovery.
- Raw material cost soared to 91.3% of revenue from 65.2% a year ago, a 2608bps headwind that crushed gross margin.
- Company remains loss-making for 5th consecutive year — cumulative losses continue to erode equity.
- Current ratio of 0.83 indicates potential short-term liquidity stress.
Research and educational content only. Not investment advice.